Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Catalyst Pharm Inc (NQ: CPRX ) 20.02 -0.20 (-1.01%) Streaming Delayed Price Updated: 3:46 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Catalyst Pharm Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Catalyst's New CEO Has Big Ideas For The Small Biotech May 10, 2024 Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. Via Investor's Business Daily CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter May 08, 2024 The company doubled Wall Street's earnings views, but sales came in short. Via Investor's Business Daily Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 May 01, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals March 27, 2024 Via Benzinga Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts March 07, 2024 Via Benzinga Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 April 22, 2024 The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day March 28, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium March 27, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Earnings Preview For Catalyst Pharmaceuticals February 27, 2024 Via Benzinga 3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List March 27, 2024 Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. Via InvestorPlace 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark March 18, 2024 On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. Via Investor's Business Daily Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) March 13, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire 3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio March 10, 2024 While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs. Via InvestorPlace Amicus Therapeutics Stock Sees RS Rating Improve To 74 March 05, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. Via Investor's Business Daily 3 Biopharma Stocks You Don't Want to Miss in the New Bull Market March 05, 2024 All three have exciting programs on the way. Via The Motley Fool Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference March 05, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Top 3 Health Care Stocks You May Want To Dump In Q1 February 29, 2024 As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. Via Benzinga Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 28, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE February 27, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology February 21, 2024 Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety... From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 February 14, 2024 The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months January 22, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc. Via Benzinga Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances January 18, 2024 With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year. Via InvestorPlace Topics Economy Exposures Economy 3 Biotech Stocks You Can Buy and Hold for the Next Decade January 15, 2024 These companies are still in the early innings of their growth potential. Via The Motley Fool Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024 January 14, 2024 With multiple drugs on the market and revenue ramping up, the sky's the limit. Via The Motley Fool Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering January 09, 2024 From Catalyst Pharmaceuticals, Inc. Via GlobeNewswire 3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January January 08, 2024 Small-cap stocks tend to outperform mid- and large-cap stocks over time and make for an important component of a balanced portfolio. Via InvestorPlace Topics Stocks Exposures US Equities < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
